Entry

D11814                      Drug

Name

Tisotumab vedotin (USAN/INN);
Tisotumab vedotin (genetical recombination) (JAN);
Tisotumab vedotin-tftv;
Tivdak (TN)

Product

TIVDAK (Seagen)

Formula

C6418H9906N1710O2022S44.(C68H106N11O15)n

Remark

Product:

D11814<US>

Efficacy

Antineoplastic

Disease

Cervical cancer [DS:H00030]

Comment

Antibody-drug conjugate

Target

F3 (CD142) [HSA:2152] [KO:K03901]
TUBB [HSA:10381 10382 10383 203068 347688 347733 7280 81027 84617] [KO:K07375]

Pathway

hsa04540

Gap junction

hsa04610

Complement and coagulation cascades

hsa04933

AGE-RAGE signaling pathway in diabetic complications

Brite

Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    F3 (CD142)
     D11814  Tisotumab vedotin (USAN/INN) <US>
Not elsewhere classified
  Cellular process
   Cytoskeleton
    TUBB
     D11814  Tisotumab vedotin (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D11814
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D11814

Other DBs

CAS:	1418731-10-8

PubChem:

405226679